PLGF Heparin Domain-Targeted Liposomes for Efficient Spleen Targeting in Breast Cancer Model

PLGF Heparin Domain-Targeted Liposomes for Efficient Spleen Targeting in Breast Cancer Model

Abstract

This study aimed to develop PLGF heparin domain-targeted liposomes and evaluate their targeting efficacy in a breast cancer model. The PLGF heparin domain was successfully synthesized and characterized using dynamic light scattering, transmission electron microscopy, and atomic force microscopy. Subsequently, the PLGF heparin domain was incorporated into liposomes through co-mixing, and the resulting PLGF heparin domain-targeted liposomes were characterized using dynamic light scattering and transmission electron microscopy. The results confirmed the successful encapsulation of the PLGF heparin domain within the liposomes.

To assess the in vivo targeting properties, the prepared PLGF heparin domain-targeted liposomes were injected into breast cancer model mice. Their distribution was monitored using fluorescence microscopy and fluorescence imaging techniques. The results revealed efficient targeting of the PLGF heparin domain-targeted liposomes to the spleen, with minimal targeting observed in other organs.

In conclusion, we have successfully developed PLGF heparin domain-targeted liposomes that demonstrate promising targeting efficacy toward the spleen in a breast cancer model. This study offers a novel approach for targeted drug delivery in breast cancer and other related diseases. Further investigation is warranted to explore the therapeutic potential of these targeted liposomes in treating breast cancer.